Expand and Enhance Prescription Drug Monitoring Programs (PDMPs)

Introductory Paragraph

Prescription Drug Monitoring Programs (PDMP) allow access timely patient-controlled substance history information by pre-registered users including:

• healthcare prescribers licensed to prescribe controlled substances
• pharmacists authorized to dispense controlled substances
• law enforcement
• regulatory boards

PDMPs are designed to collect, monitor, and analyze electronically transmitted prescribing and dispensing data submitted by pharmacies and dispensing practitioners. This information is used to assist prescribers, dispensers, and other health care professionals in making clinical decisions for their patients. PDMPs also have been shown to reduce adverse drug interactions,and help health care professionals identify patients who may be in need of substance use treatment. Law enforcement and regulatory/licensing board officials utilize PDMP information, under appropriate circumstances, to further their investigations of suspected violations of controlled substance laws and compliance with regulatory/licensing board practice standards. Many states have also begun to use PDMPs as a public health surveillance tool. PDMPs continue to be among the most promising state-level interventions to improve opioid prescribing, inform clinical practice, and protect patients at risk.

Key Information

The main objectives of PDMP programs are to:

• Improve patient safety.
• Build a data collection and analysis system at the state level.
• Enhance existing programs' ability to analyze and use collected data.
• Facilitate the exchange of collected prescription data among states.
• Assess the efficiency and effectiveness of the programs funded under this initiative.

PDMPs can alert healthcare providers to provide potentially lifesaving information and interventions.

• They DO for those using prescription opioids
  • Help collaborate with the patient to taper to a safer dosage
  • Consider offering naloxone
  • Communicate with other providers managing the patient
  • Weigh patient goals, needs, risks
• They DO for those who they consider to have opioid use disorder, discuss safety concerns and treatment options
• They DO NOT dismiss patients from care

With this in mind, states are trying to find ways to increase the use of PDMPs by prescribers, so they avoid having a mandate. In some states, you are automatically registered when practitioners apply for a license. There are also efforts to integrate PDMP data into electronic medical record systems so the information is available at the point of care.

Examples of Positive Impact

• Between the years 2010-2012, Florida implemented a PDMP and other "pill mill" policies that had a positive impact on the opioid epidemic. According to the CDC, Florida recorded a 26.1% decrease in opioid analgesic overdose deaths, after these policies were implemented. The Florida Department of Health said that from 2010 to 2013, oxycodone overdose deaths fell from 1,516 to 534—a 65% decrease.
• New York experienced a 75% decrease in prescriptions issued through "doctor shopping" as a result of a 2012 requirement that prescribers check the PDMP before writing a prescription

• 74% of California physicians reportedly changed their prescribing practice as a result of patient activity reports created using the state's PDMP

• After establishing a PDMP, Tennessee saw a reduction in the morphine milligram equivalents dispensed, a reduction in the number of doctor and pharmacy shoppers going to multiple outlets to obtain drugs, an increase in queries to the State's Controlled Substance Monitoring Database Program by prescribers and extenders, and a change in practices, with some 41.4% less likely to prescribe certain controlled substances

Examples of Negative Impact

Increased drug diversion activities in contiguous non-PDMP states. When states begin to monitor drugs, drug diversion activities tend to spill across boundaries to non-PDMP states. One example is provided by Kentucky, which shares a boundary with seven states, only two of which have PDMPs -- Indiana and Illinois. As drug diverters became aware of Kentucky PDMP's ability to trace their drug histories, they tended to move their diversion activities to nearby nonmonitored states. OxyContin diversion problems have worsened in Tennessee, West Virginia, and Virginia -- all contiguous non-PDMP states -- because of the presence of Kentucky's PDMP, according to a joint federal, state, and local drug diversion report.

 

Provider Challenges

• Insufficient Resources: Providers lack the time within their practice to perform all activities (not staffed sufficiently, not reimbursed, not value-added). Virtually every knowledge and use survey for PDMPs, for example, shows only half of physicians use the PDMP and the reasons cited for not using it are "it's too time consuming" and "it's too difficult to use." ("I need to see a patient every 12 minutes to make ends meet, I do not have the time or capacity to do all of this work.")
• Patient-Provider Relationship: The design of many programs tends to compromise the trust between patients and physicians because the providers are required to police their patients, and this is not something physicians see as part of their role as care providers. ("I did not go to medical school for this. I need a trusting relationship with the patient, which is not possible when I ask to count their pills.")
• Data Management: There is no automation support for any of this activity today, no field within the EMR to enter the risk-adjusted monitoring protocols or schedule patient activities according to risk levels, there is no place to store the results of a pill count or PDMP check or alert the physician when a treatment agreement needs to be updated.
• Consistency: Whether it is patients within a practice, practices within a network, or health systems within the state -- getting everyone to establish and adhere to protocols consistently is a challenge, yet inconsistent application of protocols is one of the greatest liabilities for any provider.

Funding Opportunities

Current Funding Methods

• Federal grants
• Private/Non-federal grants
• General revenue funds
• Controlled substance registration fees
• Professional licensing fees
• Regulatory board funds

 

 

Potential Funding Methods

• PDMP licensing fees
• Health insurance licensing fees
• Private donations
• Medicaid fraud settlements
• Assessed fines
• Asset Forfeiture
• Drug manufacturers' assessment
• Prescription fees
• Private third-party payers or health insurers
• PDMP authorized users
• See the PDMP TTAC Funding Options for Prescription Drug Monitoring Programs in Tools and Resources
  
  The Comprehensive Opioid Abuse Program Training and Technical Assistance (TTA) Program is a grant from the U.S. Bureau of Justice given to state, local, and tribal governments to provide resources to intervene with persons with substance use disorders. The goals of the Comprehensive Opioid Abuse TTA Program are twofold. First, the program aims to support site-based and state initiatives designed to reduce opioid misuse and the number of overdose fatalities. Second, the program supports PDMPs and their stakeholders in expanding the implementation, enhancement, and proactive use of prescription drug monitoring programs to support clinical decision-making and prevent the misuse and diversion of controlled substances. Proposals were due April 25, 2017.
  
  The Comprehensive Opioid Abuse Site-based Program - Harold Rogers Prescription Drug Monitoring Program Implementation and Enhancement Projects
  Funding opportunity which provides state, local, and tribal governments resources to intervene with persons with substance use disorders. The Harold Rogers Prescription Drug Monitoring Program (PDMP) is being incorporated into the FY 2017 Comprehensive Opioid Abuse Site-based Program. The purpose of this program is to improve collaboration and strategic decision-making of regulatory and law enforcement agencies and public health officials to address prescription drug and opioid misuse, save lives, and reduce crime. This is made possible through the collection and analysis of controlled substance prescription data and other scheduled chemical products through a centralized database administered by an authorized state agency. This program was applied in 2017.

 

Relevant Research

SAFE Solutions is an ever-growing platform. Currently limited information is readily available for this section. SAFE Project is dedicated to providing communities with the most relevant and innovative materials. We will continue to regularly monitor and make updates accordingly with community input and subject matter expert collaboration. Please check back soon.

Impactful Federal, State, and Local Policies

The Prescription Drug Monitoring Program was created by the FY 2002 U.S. Department of Justice Appropriations Act (Public Law 107-77).

The National Alliance for Model State Drug Laws (NAMSDL) began in 1993 as the President’s Commission on Model State Drug Laws It provides examples of PDMP laws and documents from states with prescription drug monitoring programs and provides information on:

• Annual Summaries
• Administration of PDMPs
• Data Reporting and Retention
• Types of Authorized Recipients
• Access and Registration
• PDMPs and Privacy

Available Tools & Resources

General CDC guidance on PDMPs and detailed clinical guidance

The Pew Charitable Trust created a report on Evidence-Based Practices to Optimize Use of PDMPs

Prescription Drug Monitoring Information Exchange (PMIX) Architecture enables nationwide information sharing by the use of free, open, and consensus-based solutions; common formatting of shared data; security and privacy protocols to protect sensitive information; and preserving the state choice of interstate sharing solutions.

Promising Practices

1. CURES: California's state PDMP. Learn more at CURES FAQs
2. EDIE: Oregon and Washington use the Emergency Department Information Exchange (EDIE) system. This technology allows ED practitioners to identify patients with more than 5 ER visits in a one-year period or those with complex care needs who can be directed to appropriate care. This system allows for alerts to hospitals as soon as a patient visits the ER.
3. EFORSCE: Florida's PDMP. This database has been in effect since 2010 and there are annual reports for each year. The website also includes a list of its funding sources.
4. Arizona State Board of Pharmacy Controlled Substances Prescription Monitoring Program (CSPMP) - Allows practitioners and pharmacists to look up, view, and print controlled substance dispensing information on their specific patients directly via username and password.
5. WORx Wyoming's active PDMP system.

 

Find Your State's PDMP

Use this link to find your state's Prescription Drug Monitoring Program.

TTAC

Training Technical Assistance Center: Brandeis University, in partnership with the Bureau of Justice Assistance, has developed the PDMP TTAC to provide services, support, resources, and strategies to improve the effectiveness of state PDMPs. Call 781-609-7741 for more information.

Third-Party Patient Monitoring

GuideMed Monitoring is a management program for prescription narcotics monitoring. It helps provider networks prevent prescription drug misuse and it helps to protect the network and its practitioners from liabilities associated with prescription narcotics. Patient service stations are established on-site or freestanding in locations determined by the physician, where GuideMed nurses will staff and manage the monitoring activities chosen by the physician (Risk Assessments, PDMP Checks, CSA Reviews, Pill Counts, Toxicology Testing). After the nurse gathers all the necessary information, a report is prepared and sent to the patient's physician via a PDF file attached to that patient's record. GuideMed also provides any data needed for a compliance officer.